Physicochemical Properties
| Molecular Formula | C82H103CLN18O16.XC2H4O2.XH2O |
| CAS # | 934246-14-7 |
| Related CAS # | 214766-78-6;Degarelix-d7;934016-19-0;934246-14-7 |
| SMILES | ClC1C=CC(=CC=1)C[C@H](C(N[C@H](CC1C=NC=CC=1)C(N[C@@H](CO)C(N[C@@H](CC1C=CC(=CC=1)NC([C@@H]1CC(NC(N1)=O)=O)=O)C(N[C@H](CC1C=CC(=CC=1)NC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCNC(C)C)C(N1CCC[C@H]1C(N[C@@H](C(N)=O)C)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@@H](CC1C=CC2C=CC=CC=2C=1)NC(C)=O)=O.OC(C)=O |
Biological Activity
| ln Vitro |
Degarelix exhibits the least capacity for histamine release and only very weak histamine-releasing properties when compared to other LHRH antagonists, such as Ganirelix (HY-P1628), Abarelix (HY-13534), and Cetrorelix (HY-P0009)[1]. With the exception of PC-3 cells, degarelix (1 nM-10 μM, 0-72 h) decreases cell viability in all prostate cell lines, including WPE1-NA22, WPMY-1, BPH-1, and VCaP cells [2]. Through apoptosis, degarelix (10 μM, 0-72 h) directly affects the growth of prostate cells [2]. |
| ln Vivo |
In castrated rats, degarelix (0–10 μg/kg; s.c.; once) reduces plasma testosterone and LH levels in a dose-dependent manner [3]. When incubated in cryopreserved hepatocytes and microsomes derived from animal liver tissue, degarelix remains stable. In dogs and rats, the majority of the degarelix dose is excreted in 48 hours through urine and feces in equal amounts (40–50% in each matrix); in monkeys, however, the primary excretion routes are renal (22%) and fecal (50%) [4]. |
| Cell Assay |
Assay for Cell Viability [2] Cell Lines: VCaP, LNCaP, BPH-1, WPMY-1, and WPE1-NA22 Percentage: 1 nM-10 μM Incubation Time: WPMY-1 cells at 48 and 72h, WPE1-NA22 cells at 72 hours, BPH-1 cells at 48 and 72h, LNCaP cells at 48 and 72h Result: Reduced cell viability in all prostate cell lines, with the exception of the PC-3 cells. Apoptosis Analysis[2] Cell Line: WPE1-NA22, BPH-1, LNCaP and VCaP Concentration: 10 μM Incubation Time: 24, 48 and 72 h Result: Induced a significant increase on caspase 3/7 activation. |
| Animal Protocol |
Animal Model: Male Sprague-Dawley rats, castrated[3] Dosage: 0.3, 1, 3 and 10 μg/kg or 12.5, 50, and 200 μg/kg Administration: Subcutaneous injection, once Result: produced a reduction in plasma LH levels that was both reversible and dose-dependent, with a minimum effective dose of 3 μg/kg. Tmax values were 1 and 5 hours, apparent plasma disappearance t1/2 values were 12 and 67 hours, and t1/2 of absorption values were 4 and 30 minutes for the 50 μg/kg and 200 μg/kg doses, respectively. had a minimum effective dose of 1 μg/kg and caused a dose-dependent drop in plasma testosterone levels. |